Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cyclo Therapeutics Inc - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS
Ticker
Exchange
SIC #
Website
Latest Ticker
CYTH
Nasdaq
2833
https://www.cyclotherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cyclo Therapeutics Inc
Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
- Nov 21st, 2023 1:05 pm
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
- Nov 15th, 2023 1:05 pm
Several Insiders Invested In Cyclo Therapeutics Flagging Positive News
- Nov 2nd, 2023 11:12 am
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
- Oct 30th, 2023 8:01 pm
Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million
- Oct 23rd, 2023 12:05 pm
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
- Oct 5th, 2023 12:05 pm
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
- Sep 21st, 2023 1:35 pm
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
- Sep 21st, 2023 12:05 pm
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results
- Aug 15th, 2023 12:05 pm
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
- Aug 2nd, 2023 12:16 pm
Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
- Jun 29th, 2023 5:32 pm
Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
- Jun 13th, 2023 8:01 pm
Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer’s Disease
- Jun 12th, 2023 12:05 pm
Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement
- Jun 5th, 2023 12:05 pm
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
- May 15th, 2023 12:05 pm
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)
- May 2nd, 2023 12:12 pm
Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Apr 21st, 2023 12:05 pm
Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results
- Mar 20th, 2023 12:05 pm
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
- Jan 11th, 2023 6:00 pm
Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements
- Jan 11th, 2023 1:05 pm
Scroll